Enhancing Outcomes, Reducing Costs: Evaluating Peer Support for Mood Disorders
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02242669|
Recruitment Status : Completed
First Posted : September 17, 2014
Last Update Posted : August 29, 2017
|Condition or disease|
|Depression Bipolar Disorders Mood Disorders|
|Study Type :||Observational|
|Actual Enrollment :||371 participants|
|Official Title:||Enhancing Outcomes, Reducing Costs: Evaluating Peer Support for Mood Disorders|
|Study Start Date :||November 2014|
|Actual Primary Completion Date :||April 2017|
|Actual Study Completion Date :||April 2017|
200 current DBSA participants.
60 new DBSA attendees with mood disorders who have attended their first meeting in the past month.
100 matched control group individuals with mood disorders with no current or prior exposure to DBSA.
- Systematically gather empirical estimates of the characteristics of current DBSA participants through a cross-sectional survey of demographics, clinical service, and past and current DBSA attendance, involvement, and subjective benefits. [ Time Frame: Up to 24 months ]The goal is to describe and characterize DBSA participants and obtain information on subjective benefits.
- Provide estimates of rates of attendance, retention in, and discontinuation from DBSA for new DBSA members with mood disorders. [ Time Frame: Up to 24 months ]Determine which DBSA participants are more likely to attend more frequently/become more engaged.
- Conduct a prospective between-group investigation comparing new DBSA members to a matched control group with no prior exposure to DBSA in order to test for beneficial affects of DBSA over a 6-month follow up. [ Time Frame: Up to 24 months ]Compare new DBSA members to a matched control group in order to test for any potential incremental beneficial effects from DBSA participation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02242669
|United States, Massachusetts|
|Belmont, Massachusetts, United States, 02478|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||John F Kelly, PhD||Massachusetts General Hospital|